Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2013

Promising Phase III Results for Amgen Ovarian Cancer Candidate

  • Announcing top-line results from its Phase III TRINOVA-1 trial evaluating trebananib plus paclitaxel vs. placebo plus paclitaxel in recurrent ovarian cancer, Amgen today said its drug had met its primary endpoint of progression-free survival.

    The firm observed a 34% reduction in the risk of disease progression or death in patients given trebananib plus paclitaxel, compared with placebo.

    Overall, median progression-free survival was 7.2 months with trebananib arm vs. four months in the control arm, Amgen said, noting it expects to report overall survival results in 2014.

    "Angiopoietin inhibition has been a focus of research at Amgen and these results suggest that the novel biology of trebananib may offer a promising approach for patients with ovarian cancer,” Sean E. Harper, M.D., evp of R&D at Amgen said in a statement.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »